Alloimmunization against Rh and Kell blood groups antigens is the main obstacle for blood transfusion in transfusion dependent thalassemia patients in Iran

Akbar Dorgalaleh, Mohammad Saeed Gholami, Mohammad Shokuhiyan, Mohsen Valikhani, Esmaei Saneei Moghaddam, Majid Naderi

ABSTRACT

Abstract is not required for Editorial

International Journal of Case Reports and Images (IJCRI)

International Journal of Case Reports and Images (IJCRI) is an international, peer reviewed, monthly, open access, online journal, publishing high-quality, articles in all areas of basic medical sciences and clinical specialties.

Aim of IJCRI is to encourage the publication of new information by providing a platform for reporting of unique, unusual and rare cases which enhance understanding of disease process, its diagnosis, management and clinico-pathologic correlations.

IJCRI publishes Review Articles, Case Series, Case Reports, Case in Images, Clinical Images and Letters to Editor.

Website: www.ijcasereportsandimages.com

(This page in not part of the published article.)
Alloimmunization against Rh and Kell blood groups antigens is the main obstacle for blood transfusion in transfusion dependent thalassemia patients in Iran

Akbar Dorgalaleh, Mohammad Saeed Gholami, Mohammad Shokuhian, Mohsen Valikhani, Esmaei Saneei Moghaddam, Majid Naderi

ALLOIMMUNIZATION IN THALASSEMIA MAJOR

Thalassemia is the most common inherited single-gene disorder, causes by decrease or absence of α-globin or β-globin chain production. The disorder commonly inherited in autosomal recessive manner and is more common in areas with high rate of consanguinity [1–3]. Thalassemia belt is an extensive area which extend from Mediterranean east through Middle-East and India to Southeast Asia and south through Africa. Estimated incidence of thalassemia in this area is varies from 1–20% depend on area. Iran as a Middle-East country with high rate of consanguineous marriage has a considerable number of patients with β-thalassemia major [4–6]. The precise incidence of disorder is not clear in Iran but it was estimated that there are between two and three million beta thalassemia carriers and about 20,000 patients with beta thalassemia major. The main therapeutic choice in these patients is packed red blood cell (pRBC) transfusion. Continuous blood transfusion imposed a number of transfusion related complications, most importantly iron overload and related complications as well as alloimmunization against transfused red blood cell antigens [6–10]. The reported rate of alloimmunization among transfused dependent patients with thalassemia varies between 4–50% and has a lower incidence in homologues populations. Some of these alloantibodies are important and even cause serious life-threatening transfusion related hemolytic reactions while others are clinically insignificant. Both of alloantibodies and autoantibodies may decrease survival of transfused pRBC and increase transfusion rate. Such patients may require immunosuppressive drugs, splenectomy as well as other alternative treatments. Therefore, alloimmunization and autoimmunization can significantly affect patients' quality of life and overall survival [11–13].

ALLOIMMUNIZATION IN THALASSEMIA MAJOR IN IRAN

A considerable number of studies were performed in patients with β-thalassemia major in different areas of Iran. The most common used method for detection of alloimmunization, was conventional tube technique (~80%), while gel method was used in minority (~20%) [5–8]. In the majority of studies, in addition to alloantibodies, autoantibody (8 out of 13 studies) (61.5%) also were detected [1, 3, 4, 12]. Among these studies, the rate of autoimmunization ranges from 1–~19% [4, 9]. The rate of alloimmunization varied between ~3–76%. The lower incidence of alloimmunization was reported in Tehran province, while the highest incidence was observed in Isfahan province [6, 9]. Among alloantibodies the majorities are against Rh and Kell blood group systems. The prevalence of alloantibody against Rh system ranged from 7.5–100% and this prevalence for Kell system varied from 14–60% [3]. Among these studies on Iranian patients, the rate of splenectomy was reported from ~8–100%. The rate of alloimmunization against these totally splenectomized patients was ~4% (Table 1).

In Rh blood group system, most of antibodies directed against, E, C and c antigens respectively, while in Kell blood group system the majority were directed against K antigen (Table 2).
Table 1: Prevalence of splenectomy and hemolytic reaction among Iranian patients with thalassemia major

<table>
<thead>
<tr>
<th>Study</th>
<th>Splenectomy</th>
<th>Without splenectomy</th>
<th>Hemolytic reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>28 (7.3%)</td>
<td>375 (92.7%)</td>
<td>Without hemolytic reaction</td>
</tr>
<tr>
<td>2</td>
<td>18 (25.7%)</td>
<td>52 (74.3%)</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>346 (41.4%)</td>
<td>489 (58.6%)</td>
<td>21 (2.5%)</td>
</tr>
<tr>
<td>4</td>
<td>222 (50.3%)</td>
<td>219 (49.6%)</td>
<td>7 (1.6%)</td>
</tr>
<tr>
<td>5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>9 (17.3%)</td>
<td>43 (82.7%)</td>
<td>-</td>
</tr>
<tr>
<td>7</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>8</td>
<td>28 (21%)</td>
<td>105 (78.9%)</td>
<td>-</td>
</tr>
<tr>
<td>9</td>
<td>80 (100%)</td>
<td>-</td>
<td>11 (13.75%)</td>
</tr>
<tr>
<td>10</td>
<td>7</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>11</td>
<td>10 (8.3%)</td>
<td>111 (91.7%)</td>
<td>-</td>
</tr>
<tr>
<td>12</td>
<td>17 (34.7%)</td>
<td>32 (65.3%)</td>
<td>-</td>
</tr>
<tr>
<td>13</td>
<td>203 (28.5%)</td>
<td>508 (71.5%)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>961</td>
<td>1934</td>
<td>39 (2.8%)</td>
</tr>
</tbody>
</table>

*All of the patients had their spleen removed prior to the time of antibody formation.

Table 2: Prevalence of alloimmunization and autoimmunization among Iranian patients with β-thalassemia major

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of patients</th>
<th>Gender</th>
<th>Mean age</th>
<th>Province</th>
<th>Method</th>
<th>Allo-antibody</th>
<th>Auto-antibody</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>385</td>
<td>Male: 221, Female: 164</td>
<td>13.8 y</td>
<td>Sistan and Baluchestan</td>
<td>Conventional</td>
<td>69 (17.9%)</td>
<td>Rh: 49.1%, Kell: 14%, Leu: 10.5%</td>
<td>Single: 21 (5.5%)</td>
</tr>
<tr>
<td>2</td>
<td>70</td>
<td>Male: 31, Female: 39</td>
<td>16 y</td>
<td>Khuzestan</td>
<td>Conventional</td>
<td>6 (8.6%)</td>
<td>Rh: 50%, Kell: 50%</td>
<td>Single: -</td>
</tr>
<tr>
<td>3</td>
<td>835 (Adult 548, Pediatric 287)</td>
<td>Male: 416, Female: 419</td>
<td>Adult (24.5 y), Pediatric (10 y)</td>
<td>Tehran, Gel</td>
<td>100 (11.9%)</td>
<td>Rh: 45%, Kell: 34%, Colton: 2%</td>
<td>Single: 72%, Double: 19%, Triple: 3%, UD: 6%</td>
<td>1 (%)</td>
</tr>
<tr>
<td>4</td>
<td>441</td>
<td>Male: 234, Female: 207</td>
<td>22 y</td>
<td>Tehran + Qazvin, Gel</td>
<td>50 (11.3%)</td>
<td>Rh: 42%, Kell: 28%</td>
<td>Single: 74%, Double: 16%, UD: 8%</td>
<td>Single: 1 (%)</td>
</tr>
<tr>
<td>5</td>
<td>458</td>
<td>Male: 221, Female: 237</td>
<td>16.96 y</td>
<td>Tehran, Gel</td>
<td>49 (11.8%)</td>
<td>Rh: 47%</td>
<td>Kell: 35%</td>
<td>Single: 71.5%, Double: 14.3%, UD: 14.2%</td>
</tr>
<tr>
<td>6</td>
<td>52</td>
<td>Male: 36, Female: 16</td>
<td>18.2 y</td>
<td>Isfahan</td>
<td>Conventional</td>
<td>40 (76%)</td>
<td>Kell: 27.5%, MNSs: 20%, Rh: 7.5%</td>
<td>Single: 67.5%, Multiple: 27.5%, UD: 5%</td>
</tr>
<tr>
<td>7</td>
<td>218</td>
<td>Male: 100, Female: 118</td>
<td>22.5 y</td>
<td>Mazandaran</td>
<td>Conventional</td>
<td>88 (40.4%)</td>
<td>Rh: 75%, Le: 64%</td>
<td>Single: 47%</td>
</tr>
<tr>
<td>8</td>
<td>133</td>
<td>Male: 66, Female: 67</td>
<td>17.5 y</td>
<td>Khuzestan</td>
<td>Conventional</td>
<td>25 (18.7%)</td>
<td>Rh: 55%, Kell: 33%</td>
<td>Single: 72%, Double: 20%, Triple: 8%</td>
</tr>
<tr>
<td>9</td>
<td>80</td>
<td>Male: 37, Female: 43</td>
<td>8.35 y</td>
<td>Tehran</td>
<td>Conventional</td>
<td>3 (3.7%)</td>
<td>Rh: 67%, Kell: 33%</td>
<td>Single: 15</td>
</tr>
</tbody>
</table>
Table 3: Prevalence of alloimmunization and autoimmunization among different countries

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Sample Size</th>
<th>Mean Age</th>
<th>Gel</th>
<th>Conventional</th>
<th>Male</th>
<th>Female</th>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmed et al. 2010</td>
<td>Egypt</td>
<td>501</td>
<td>10.84 y</td>
<td>Gel and Conventional</td>
<td>57 (11.3%)</td>
<td>Kell: 35%</td>
<td>E: 29.9%</td>
<td>Single: 145 (28.9%)</td>
</tr>
<tr>
<td>Haslina et al. 2004</td>
<td>Malaysia</td>
<td>63</td>
<td>Adult (24.5 y)</td>
<td>Conventional</td>
<td>-</td>
<td>-</td>
<td>Single: 1 (1.6%)</td>
<td></td>
</tr>
<tr>
<td>Pahuja et al. 2008-2009</td>
<td>India</td>
<td>211</td>
<td>Adult &gt; 5 y</td>
<td>Conventional</td>
<td>8 (3.79%)</td>
<td>Kell: 25%</td>
<td>E: 25%</td>
<td>Single: 75% Double: 25%</td>
</tr>
<tr>
<td>Al-Mousawi et al. 2014</td>
<td>Iraq</td>
<td>401</td>
<td>10.0 y</td>
<td>Conventional</td>
<td>18 (4.5%)</td>
<td>Rh: Kell</td>
<td>E: 6 (30%) D: 4 (20%)</td>
<td>Single: 88.9% Double: 11.1%</td>
</tr>
<tr>
<td>S. Jansuwan et al. 2013</td>
<td>Northern Thailand</td>
<td>143</td>
<td>16.0 y</td>
<td>Gel and Conventional</td>
<td>24 (16.8%)</td>
<td>Rh: E: 13 (54.2%) C: 4 (16.7%)</td>
<td>Single: 68% Double: 24% Triple: 8%</td>
<td></td>
</tr>
<tr>
<td>Kocyigit C et al. 2011-2012</td>
<td>Turkey</td>
<td>139</td>
<td>Adult &gt; 2</td>
<td>Conventional</td>
<td>9 (6.4%)</td>
<td>Rh: Kell Kidd</td>
<td>C: 27% D: 18% JKa:18% E: 9%</td>
<td>Single: 77.8% Double: 22.2%</td>
</tr>
<tr>
<td>Dogra, et al. 2009-2010</td>
<td>Jammu region</td>
<td>70</td>
<td>9.27 y</td>
<td>Conventional</td>
<td>6 (7.5%)</td>
<td>Rh: Kell</td>
<td>E: 50% C: 33-3 D: 16.7</td>
<td>Single: 1 (1.42%)</td>
</tr>
<tr>
<td>AMEEN et al. 2002</td>
<td>Kuwaiti Arab and non Kuwaiti Arab</td>
<td>190</td>
<td>12.7 y</td>
<td>Conventional</td>
<td>142 (74.74%)</td>
<td>Kell: Rh</td>
<td>E: 41 (72%) D: 26 (45.6%)</td>
<td>25 (43.8%)</td>
</tr>
<tr>
<td>Hassan et al. 2003</td>
<td>Pakistan</td>
<td>75</td>
<td>6.5 y</td>
<td>Conventional</td>
<td>17 (22.7%)</td>
<td>Kell: Rh</td>
<td>Kpa: 4 (23.5%) e: 3 (17.6%) E: 2 (11.8%)</td>
<td>22</td>
</tr>
<tr>
<td>L-Y. Wang et al. 2005</td>
<td>Taiwan</td>
<td>30</td>
<td>20 y</td>
<td>Conventional</td>
<td>11 (37%)</td>
<td>Rh</td>
<td>E: 7 (63.6) C: 2 (18.2%)</td>
<td>Single: 72.8% Double: 27.2%</td>
</tr>
<tr>
<td>N. Guirat-Dhouib et al. 2011</td>
<td>Tunisia</td>
<td>130</td>
<td>9.9 y</td>
<td>Conventional</td>
<td>10 (7.7%)</td>
<td>Rh</td>
<td>E: 3 (30%) C: 3 (30%)</td>
<td>Single: 80% Double: 20%</td>
</tr>
<tr>
<td>Muhammad USMAN et al. 2011</td>
<td>Pakistan</td>
<td>800</td>
<td>11.5 y</td>
<td>Conventional</td>
<td>30 (3.75%)</td>
<td>Rh</td>
<td>D: 8 (26.6%) E: 7 (23.3%) C: 6 (20%)</td>
<td>25</td>
</tr>
<tr>
<td>Th. Spanosa et al.</td>
<td>Greece</td>
<td>1200</td>
<td>11.5 y</td>
<td>Conventional</td>
<td>220 (22.6%)</td>
<td>Rh: Kell</td>
<td>134 (28.5%) E: 66 (14%)</td>
<td>Single: 51.8% Double: 19.1% Triple: 13.6% More than three: 15.5</td>
</tr>
</tbody>
</table>

*calculated
COMPARISON BETWEEN ALLOIMMUNIZATION IN IRAN WITH OTHER COUNTRIES

Similar to Iran the most common antibodies against transfused red blood cells were anti-Rh and anti-Kell antibodies in other countries [14–22]. The rate of alloimmunization varies between these countries from ~4% in India and Pakistan to ~75% in Kuwait [16, 21, 22]. Similar to Iran, conventional tube method is the most commonly used method for antibody detection and identification in other countries [23–26]. Although as low as 0.7% of autoantibody was reported in other countries, most studies reported a significantly higher incidence of autoimmunization in other countries [18, 22–25]. In Kell blood group system, the most commonly alloantibodies directed against K antigen [14, 18–20]. In Rh blood group system, majority of antibody directed against D, E and C antigens (Table 3). With regards to these studies it seems that alloimmunization and even autoimmunization are a major concern in transfusion dependent thalassemia patients [5, 7, 22]. In Iranian patients with β-thalassemia major, transfusion related reaction was reported with a prevalence of about 15% in some studies [15, 20]. Sometime, in patients with alloimmunization is significant and can have life-threatening consequences. In emergency situations, appropriate blood selection is really difficult and required sophisticated laboratory investigations that only can be performed in specialized laboratories. In addition to this condition, clinically significant alloantibodies and autoantibodies can affect quality of life of these patients and affect overall survival of patients with β-thalassemia major. To prevent such conditions, its appropriate to use more suitable preventable strategies such as phenotyping of patients prior to beginning blood transfusion and used of relatively complete matched pRBC. Another way to prevent, is application of direct donation instead of random pRBC transfusion that increase the rate of alloimmunization and related consequences.

Keywords: Alloimmunization, Blood transfusion, Kell, Rh, β-thalassemia major

How to cite this article


Article ID: Z01201706ED10008AD

doi:10.5348/ijcri-201708-ED-10008

Acknowledgements

We appreciate all patients with thalassemia that taking part in our researches and improved our knowledge about different aspects of thalassemia.

Author Contributions

Akbar Dorgalaleh – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Mohammad Saeed Gholami – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Mohammad Shokuhiyan – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Mohsen Valikhani – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Esmaei Saneei Moghaddam – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Majid Naderi – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor

The corresponding author is the guarantor of submission.

Conflict of Interest

Authors declare no conflict of interest.

Copyright

© 2017 Akbar Dorgalaleh et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES

of erythrocyte alloantibodies in patients with thalassemia major referred to Ahvaz Shafa hospital. Feyz Journals of Kashan University of Medical Sciences 2013;17(2).
About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.*

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.*

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

* Terms and condition apply. Please see Edorium Journals website for more information.

We welcome you to interact with us, share with us, join us and of course publish with us.

EDORIUM JOURNALS
AN INTRODUCTION

Edorium Journals: An introduction
Edorium Journals Team

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

* Terms and condition apply. Please see Edorium Journals website for more information.

We welcome you to interact with us, share with us, join us and of course publish with us.

Edorium Journals: On Web
Browse Journals

CONNECT WITH US

This page is not a part of the published article. This page is an introduction to Edorium Journals and the publication services.